Published in Epilepsy Res on November 01, 2004
An HSV vector system for selection of ligand-gated ion channel modulators. Nat Methods (2007) 1.57
Post-stroke fatigue: a deficit in corticomotor excitability? Brain (2014) 0.86
Altered cortical inhibitory function in children with spastic diplegia: a TMS study. Exp Brain Res (2008) 0.82
L-dopa modulates motor cortex excitability in Alzheimer's disease patients. J Neural Transm (Vienna) (2008) 0.80
Effects of repetitive transcranial magnetic stimulation in a patient with fixation-off sensitivity. Exp Brain Res (2006) 0.77
Lamotrigine and levetiracetam exert a similar modulation of TMS-evoked EEG potentials. Epilepsia (2016) 0.75
Altered paired associative stimulation-induced plasticity in NMDAR encephalitis. Ann Clin Transl Neurol (2016) 0.75
The variability of motor evoked potential latencies in neurosurgical motor mapping by preoperative navigated transcranial magnetic stimulation. BMC Neurosci (2017) 0.75
15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet (2009) 6.21
Pharmacological approach to the mechanisms of transcranial DC-stimulation-induced after-effects of human motor cortex excitability. Brain (2002) 4.53
Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain (2009) 3.96
A proposal for a five-dimensional patient-oriented epilepsy classification. Epileptic Disord (2005) 3.94
Facilitation of implicit motor learning by weak transcranial direct current stimulation of the primary motor cortex in the human. J Cogn Neurosci (2003) 3.75
Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol (2007) 2.99
Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer (2009) 2.98
Modulating parameters of excitability during and after transcranial direct current stimulation of the human motor cortex. J Physiol (2005) 2.89
Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci (2004) 2.84
Safety criteria for transcranial direct current stimulation (tDCS) in humans. Clin Neurophysiol (2003) 2.83
The REM sleep behavior disorder screening questionnaire--a new diagnostic instrument. Mov Disord (2007) 2.64
Modulation of cortical excitability by weak direct current stimulation--technical, safety and functional aspects. Suppl Clin Neurophysiol (2003) 2.56
Level of action of cathodal DC polarisation induced inhibition of the human motor cortex. Clin Neurophysiol (2003) 2.51
Status epilepticus: a critical review. Epilepsy Behav (2009) 2.36
Prognostic significance of serum cholesterol levels in patients with idiopathic dilated cardiomyopathy. Eur Heart J (2005) 2.11
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain (2005) 2.06
Cabergoline versus levodopa monotherapy: a decision analysis. Mov Disord (2003) 2.03
Cavernoma-related epilepsy: review and recommendations for management--report of the Surgical Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia (2013) 2.00
Hyperalgesia and functional sensory loss in restless legs syndrome. Pain (2013) 2.00
Epilepsy, hippocampal sclerosis and febrile seizures linked by common genetic variation around SCN1A. Brain (2013) 1.95
Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol (2008) 1.83
The pRb/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc Natl Acad Sci U S A (2007) 1.78
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
GABAergic modulation of DC stimulation-induced motor cortex excitability shifts in humans. Eur J Neurosci (2004) 1.72
Proposal: different types of alteration and loss of consciousness in epilepsy. Epilepsia (2014) 1.66
Costs of illness and care in Parkinson's disease: an evaluation in six countries. Eur Neuropsychopharmacol (2011) 1.60
NK and CD4+ T cell changes in blood after seizures in temporal lobe epilepsy. Exp Neurol (2008) 1.59
Gene expression profiling of Lewy body-bearing neurons in Parkinson's disease. Exp Neurol (2005) 1.58
Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia (2009) 1.58
Consolidation of human motor cortical neuroplasticity by D-cycloserine. Neuropsychopharmacology (2004) 1.55
H-coil: Induced electric field properties and input/output curves on healthy volunteers, comparison with a standard figure-of-eight coil. Clin Neurophysiol (2009) 1.54
Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord (2005) 1.54
Timing-dependent modulation of associative plasticity by general network excitability in the human motor cortex. J Neurosci (2007) 1.54
Intrathecal application of autologous bone marrow cell preparations in Parkinsonian syndromes. Mov Disord (2012) 1.50
Serum concentrations of s100b and NSE in migraine. Headache (2009) 1.48
Peritrigonal and temporo-occipital heterotopia with corpus callosum and cerebellar dysgenesis. Neurology (2012) 1.48
Genome-wide association analysis of genetic generalized epilepsies implicates susceptibility loci at 1q43, 2p16.1, 2q22.3 and 17q21.32. Hum Mol Genet (2012) 1.48
Long-term assessment of striatal dopamine transporters in Parkinsonian patients with intrastriatal embryonic mesencephalic grafts. Eur J Nucl Med Mol Imaging (2006) 1.46
Limited impact of homeostatic plasticity on motor learning in humans. Neuropsychologia (2008) 1.45
Anticonvulsant effects of transcranial direct-current stimulation (tDCS) in the rat cortical ramp model of focal epilepsy. Epilepsia (2006) 1.41
Memory for public events in patients with unilateral temporal lobe epilepsy. Epilepsy Behav (2010) 1.41
Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain (2002) 1.37
Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A (2009) 1.35
Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol (2007) 1.34
Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Mov Disord (2008) 1.33
Extracorporeal shock wave therapy for plantar fasciitis: randomised controlled multicentre trial. BMJ (2003) 1.32
Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci (2003) 1.30
Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann Neurol (2002) 1.29
The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem (2005) 1.27
Catecholaminergic consolidation of motor cortical neuroplasticity in humans. Cereb Cortex (2004) 1.26
Cytokines and epilepsy. Seizure (2011) 1.26
Dopaminergic modulation of long-lasting direct current-induced cortical excitability changes in the human motor cortex. Eur J Neurosci (2006) 1.25
Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults. Nat Neurosci (2011) 1.24
Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain (2003) 1.24
Modern technology calls for a modern approach to classification of epileptic seizures and the epilepsies. Epilepsia (2012) 1.24
The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord (2014) 1.20
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice. Exp Neurol (2007) 1.20
Timecourse of health-related quality of life as determined 3, 6 and 12 months after stroke. Relationship to neurological deficit, disability and depression. J Neurol (2002) 1.20
Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [(11)C] (R)-PK11195 PET (MEMSA-trial). Mov Disord (2010) 1.18
Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci (2007) 1.18
Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines. Parkinsonism Relat Disord (2010) 1.16
Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats. J Neurochem (2003) 1.15
Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord (2009) 1.15
Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers. Parkinsonism Relat Disord (2011) 1.15
Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord (2011) 1.14
Cost of epilepsy: a systematic review. Pharmacoeconomics (2008) 1.13
Cost of illness and its predictors for Parkinson's disease in Germany. Pharmacoeconomics (2005) 1.13
Rational therapeutic approaches to progressive supranuclear palsy. Brain (2010) 1.11
Processing stages underlying word recognition in the anteroventral temporal lobe. Neuroimage (2006) 1.10
Continuous phenobarbital treatment leads to recurrent plantar fibromatosis. Epilepsia (2008) 1.10
Management and long-term outcome in patients presenting with ictal asystole or bradycardia. Epilepsia (2011) 1.09
Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord (2005) 1.09
Partial support for ZNF804A genotype-dependent alterations in prefrontal connectivity. Hum Brain Mapp (2011) 1.09
Lack of differences of motorcortical excitability in the morning as compared to the evening in juvenile myoclonic epilepsy--a study using transcranial magnetic stimulation. Epilepsy Res (2007) 1.07
Attitudes and barriers to clinical practice guidelines in general and to the guideline on Parkinson's disease. A National Survey of German neurologists in private practice. J Neurol (2009) 1.06
Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. J Neurosci (2006) 1.04
Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol (2009) 1.04
Treatment of paroxysmal dyskinesias. Expert Opin Pharmacother (2010) 1.04
Naturally occurring α-synuclein autoantibody levels are lower in patients with Parkinson disease. Neurology (2012) 1.04
Evaluation of costs and outcome in cardioembolic stroke or TIA. J Neurol (2009) 1.04
Neuronal tissue polarization induced by repetitive transcranial magnetic stimulation? Neuroreport (2002) 1.03
Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci Transl Med (2012) 1.02
Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. Mov Disord (2003) 1.01